Oral Semaglutide vs Empagliflozin: PIONEER 2 Study
- Ms. Tanvi Goel
- Sep 9
- 1 min read
Updated: Sep 10
Rodbard HW et al conducted the PIONEER 2 clinical study to assess the efficacy of oral Semaglutide in comparison with Empagliflozin in patients with Type 2 diabetes uncontrolled on Metformin. Investigators studied the impact on HbA1c reduction and mean change in body weight from baseline.
Study Summary
About the Author
Ms. Tanvi Goel is a Medical Writer with a master’s degree in pharmaceutical science. Tanvi has experience in scientific and regulatory writing and is eager to learn more about novel pharmacological agents.
Abbreviations
A1C: Glycated hemoglobin; ETD: estimated treatment difference; GLP - 1: Glucose like peptide 1; SGLT2i: Sodium-glucose cotransporter-2 inhibitors;
Reference
Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, et al.; PIONEER 2 Investigators. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019 Dec;42(12):2272-2281.
Disclaimer
The matter published on this platform has been developed by independent medical writers from various healthcare backgrounds including members of MedWriters Alumni Network. Although great care has been taken in compiling and checking the information, the authors, Rxnews team and its partners or agents, and sponsors shall not be responsible or in any way liable for any errors, omissions, or inaccuracies in this blog article whether arising from negligence or otherwise, however or for any consequences arising therefrom. The inclusion and exclusion of any product do not mention that the publisher advocates or rejects its use generally or in any particular field or field. For any complaints or feedback please write to content@rxnews.in
Comments